Business
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
SOUTH SAN FRANCISCO, Calif., January 28, 2026--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026.
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/da6b56ed061608fe0919fc3ce36cc450"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1tIhIuGs2q0NKaZQ5IHqzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/da6b56ed061608fe0919fc3ce36cc450","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/PNEH4JK6IFDN042Wd7lapA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/da6b56ed061608fe0919fc3ce36cc450","width":1121,"height":442}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 28, 2026--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026.","length":509,"tagName":"p"},{"type":"text","content":"The objective of the data analysis was to describe the safety profile of long-term use of the company’s lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in children with A-T who received eDSP for a minimum of two years. Key highlights reported in the poster presentation, titled Safety of Long-Term Treatment of Children with Ataxia Telangiectasia (A-T) with Encapsulated Dexamethasone Sodium Phosphate (eDSP), include:","length":434,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Long-term treatment with eDSP in children with A-T was associated with stable growth and metabolic parameters without indications of corticosteroid-related toxicities.","length":167,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":167,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Height and weight z-scores stabilized during treatment with eDSP and no corticosteroid-related linear growth suppression or weight increase were observed. Progressive growth faltering is a typical charact...